Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of...
REDWOOD CITY, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of...
Advanced to Cohort 6 in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersAbstract accepted for BDC-4182, a claudin 18.2-targeting BoltbodyTM ISAC at the...
BOLT SHAREHOLDER ALERT: Edelson Lechtzin LLP Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Shareholders to Consult Legal Counsel About the Pending Securities Fraud Class Action PR...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.007 | -1.12 | 0.625 | 0.655 | 0.6087 | 145582 | 0.62506015 | CS |
4 | -0.0703 | -10.2135696644 | 0.6883 | 0.7 | 0.6087 | 143983 | 0.64578111 | CS |
12 | -0.1187 | -16.1123931044 | 0.7367 | 0.78 | 0.6087 | 165812 | 0.70203306 | CS |
26 | -0.552 | -47.1794871795 | 1.17 | 1.56 | 0.6087 | 197709 | 0.84648213 | CS |
52 | -0.482 | -43.8181818182 | 1.1 | 1.56 | 0.6087 | 163950 | 0.93382973 | CS |
156 | -14.602 | -95.9395532194 | 15.22 | 15.22 | 0.6087 | 203744 | 2.47558047 | CS |
260 | -21.372 | -97.1896316508 | 21.99 | 43.07 | 0.6087 | 194517 | 6.88164602 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.